Algernon Pharmaceuticals (TSE:AGN) has released an update.
Algernon Pharmaceuticals, a Canadian drug development firm, is set to present promising Phase 1 clinical trial data for DMT as a stroke treatment at the upcoming Interdisciplinary Conference on Psychedelic Research. The study highlighted the safety and tolerability of sub-psychedelic doses of DMT and its potential to promote neuroplasticity. Encouraged by these results, the company is gearing up for a Phase 2a trial in stroke patients later in the year.
For further insights into TSE:AGN stock, check out TipRanks’ Stock Analysis page.
